Drug Search Results
More Filters [+]

Taspoglutide

Alternative Names: taspoglutide
Latest Update: 2021-11-27
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: GLP-1 Agonist

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: Subcutaneous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Taspoglutide

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Type 2 Diabetes|General Diabetes

Phase 2: Type 2 Diabetes

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2011-001935-21

P3

Completed

General Diabetes

2011-12-21

BC21625

P3

Completed

Type 2 Diabetes

2011-03-01

BC21713

P3

Completed

Type 2 Diabetes

2011-03-01

ND

P3

Terminated

Type 2 Diabetes

2011-01-31

Recent News Events